Embryonic stem cell therapy-Eye disorders - Regenerative Patch Technologies

Drug Profile

Embryonic stem cell therapy-Eye disorders - Regenerative Patch Technologies

Alternative Names: CPCB-RPE1; hESC-RPE Synthetic Substrate Patch

Latest Information Update: 19 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regenerative Patch Technologies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dry age-related macular degeneration

Most Recent Events

  • 13 Apr 2016 Immunogenicity data from preclinical studies in Dry age-related macular degeneration released by Regenarative Patch Technology
  • 01 Oct 2015 Phase-I/II clinical trials in Dry Age-related macular degeneration in USA (Intraocular)
  • 01 Oct 2015 Preclinical trials in Dry age-related macular degeneration in USA (Intraocular) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top